Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 09/22 11:44:11 am
17.31 EUR   -0.35%
09/06 PCAS : Résultats au 1er semestre 2017
09/05 NOMBRE TOTAL DE : Août 2017
09/01PCAS SA : half-yearly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

PCAS : Extension of the manufacturing between VLG Chem and Sanofi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/29/2011 | 11:11am CEST
Extension of the manufacturing contract between VLG Chem and  Sanofi until 2015 The PCAS Group and the Sanofi Group have signed an agreement on the extension of the manufacturing contract related to VLG Chem, a 100% PCAS subsidiary, until 2015. About PCAS PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.
Longjumeau, december 27th, 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
09/06 PCAS : Résultats au 1er semestre 2017
09/05 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Août 2017
09/01PCAS SA : half-yearly earnings release
08/22 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Juillet 2017
07/27 PCAS : End of the liquidity contract between PCAS and KEPLER CHEUVREUX
07/19 PCAS : sustained growth in net sales
07/05 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Juin 2017
07/03 PCAS : ex-dividend day for final dividend
06/06 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Mai 2017
05/18 PCAS : Document de référence 2016
More news
Financials (€)
Sales 2017 208 M
EBIT 2017 19,1 M
Net income 2017 10,4 M
Debt 2017 46,1 M
Yield 2017 1,27%
P/E ratio 2017 23,16
P/E ratio 2018 17,37
EV / Sales 2017 1,49x
EV / Sales 2018 1,35x
Capitalization 263 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 17,0 €
Spread / Average Target -2,3%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PCAS23.89%315
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914